Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 3
1997 2
2003 4
2004 1
2005 1
2008 1
2009 1
2010 4
2011 1
2017 2
2018 1
2019 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

21 results
Results by year
Filters applied: . Clear all
Page 1
Acute calculous cholecystitis: Review of current best practices.
Gomes CA, Junior CS, Di Saverio S, Sartelli M, Kelly MD, Gomes CC, Gomes FC, Corrêa LD, Alves CB, Guimarães SF. Gomes CA, et al. Among authors: correa ld. World J Gastrointest Surg. 2017 May 27;9(5):118-126. doi: 10.4240/wjgs.v9.i5.118. World J Gastrointest Surg. 2017. PMID: 28603584 Free PMC article. Review.
Cost-utility of reduction mammoplasty in Brazilian public service using BREAST-Q®.
Corrêa MPD, Dornelas MT, Cruz PHR, da Silva PV, Pedrosa NV, de Oliveira YM, Corrêa LD, Chaoubah A. Corrêa MPD, et al. Among authors: correa ld. J Plast Reconstr Aesthet Surg. 2019 Jul;72(7):1219-1243. doi: 10.1016/j.bjps.2019.02.018. Epub 2019 Mar 5. J Plast Reconstr Aesthet Surg. 2019. PMID: 30956129 Clinical Trial. No abstract available.
Assessment of quality of life in patients who underwent breast reduction using BREAST-Q.
Corrêa MPD, Dornelas MT, de Carvalho EN, Barra A, Venturelli EP Jr, Corrêa LD, Chaoubah A. Corrêa MPD, et al. Among authors: correa ld. J Plast Reconstr Aesthet Surg. 2018 Jun;71(6):929-931. doi: 10.1016/j.bjps.2018.02.010. Epub 2018 Mar 1. J Plast Reconstr Aesthet Surg. 2018. PMID: 29525362 No abstract available.
In vitro and in vivo pharmacology of NXT629, a novel and selective PPARα antagonist.
Stebbins KJ, Broadhead AR, Cabrera G, Correa LD, Messmer D, Bundey R, Baccei C, Bravo Y, Chen A, Stock NS, Prasit P, Lorrain DS. Stebbins KJ, et al. Among authors: correa ld. Eur J Pharmacol. 2017 Aug 15;809:130-140. doi: 10.1016/j.ejphar.2017.05.008. Epub 2017 May 5. Eur J Pharmacol. 2017. PMID: 28483457
Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist.
Swaney JS, Chapman C, Correa LD, Stebbins KJ, Broadhead AR, Bain G, Santini AM, Darlington J, King CD, Baccei CS, Lee C, Parr TA, Roppe JR, Seiders TJ, Ziff J, Prasit P, Hutchinson JH, Evans JF, Lorrain DS. Swaney JS, et al. Among authors: correa ld. J Pharmacol Exp Ther. 2011 Mar;336(3):693-700. doi: 10.1124/jpet.110.175901. Epub 2010 Dec 15. J Pharmacol Exp Ther. 2011. PMID: 21159750
Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation.
Lorrain DS, Bain G, Correa LD, Chapman C, Broadhead AR, Santini AM, Prodanovich PP, Darlington JV, Stock NS, Zunic J, King CD, Lee C, Baccei CS, Stearns B, Roppe J, Hutchinson JH, Prasit P, Evans JF. Lorrain DS, et al. Among authors: correa ld. Eur J Pharmacol. 2010 Aug 25;640(1-3):211-8. doi: 10.1016/j.ejphar.2010.05.003. Epub 2010 May 21. Eur J Pharmacol. 2010. PMID: 20519143
Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammation.
Lorrain DS, Bain G, Correa LD, Chapman C, Broadhead AR, Santini AM, Prodanovich P, Darlington JV, Hutchinson JH, King C, Lee C, Baccei C, Li Y, Arruda JM, Evans JF. Lorrain DS, et al. Among authors: correa ld. J Pharmacol Exp Ther. 2009 Dec;331(3):1042-50. doi: 10.1124/jpet.109.158089. Epub 2009 Sep 11. J Pharmacol Exp Ther. 2009. PMID: 19749079
21 results